Ebola in west Africa

The Lancet Infectious Diseases

Volumn 14, Issue 11, 2014, Pages 1045-

  Trad, Mohamad Ali ^a   Fisher, Dale Andrew ^a   Tambyah, Paul Anantharajah ^a  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; FAVIPIRAVIR; MB 003; OSELTAMIVIR; TROVAFLOXACIN; UNCLASSIFIED DRUG;

AFRICA; ANTIVIRAL THERAPY; CASE FINDING; DRUG EFFICACY; EBOLA HEMORRHAGIC FEVER; EBOLA VIRUS; EPIDEMIC; HUMAN; INFECTION PREVENTION; INFLUENZA; LETTER; MENINGITIS; TREATMENT RESPONSE; VIRAL CLEARANCE; WEST AFRICA; WEST AFRICAN; HEMORRHAGIC FEVER, EBOLA;

DISEASE OUTBREAKS; HEMORRHAGIC FEVER, EBOLA; HUMANS;

EID: 84908279078     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(14)70924-7     Document Type: Letter

References (5)

1. Ebola in west Africa. Lancet Infect Dis 2014, 14:779. The Lancet Infectious Diseases.
2. Global outbreak and response network WHO, (accessed Aug 20, 2014). http://who.int/csr/disease/ebola/en.
3. Oestereich L, Lüdtke A, Wurr S, Rieger T, Muñoz-Fontela C, Günther S Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Res 2014, 105:17-21.
4. Jefferson T, Doshi P Multisystem faulure: the story of anti-influenza drugs. BMJ 2014, 348:g2263.
5. Lenzer J Pfizer settles with victims of Nigerian drug trial. BMJ 2011, 343:d5268.